https://www.selleckchem.com/pr....oducts/Simvastatin(Z
group, and -87·8% for the 30 mg group (all p0·0001). Effects were stable over the 24-week treatment period. Dose-dependent reductions were also observed for fibrinogen, serum amyloid A, haptoglobin, secretory phospholipase A2, and lipoprotein(a). Ziltivekimab was well tolerated, did not affect the total cholesterol to HDL cholesterol ratio, and there were no serious injection-site reactions, sustained grade 3 or 4 neutropenia or thrombocytopenia. Ziltivekimab markedly reduced biomarkers of inflammation and thrombosis rele
Like
Comment
Share
